M. Ruer‐Mulard

812 total citations · 1 hit paper
18 papers, 522 citations indexed

About

M. Ruer‐Mulard is a scholar working on Immunology, Dermatology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, M. Ruer‐Mulard has authored 18 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 10 papers in Dermatology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in M. Ruer‐Mulard's work include Psoriasis: Treatment and Pathogenesis (13 papers), Dermatology and Skin Diseases (9 papers) and Pharmaceutical studies and practices (4 papers). M. Ruer‐Mulard is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (13 papers), Dermatology and Skin Diseases (9 papers) and Pharmaceutical studies and practices (4 papers). M. Ruer‐Mulard collaborates with scholars based in France, United States and Germany. M. Ruer‐Mulard's co-authors include Simon Cooper, Jörg C. Prinz, Alice B. Gottlieb, Külli Kingo, Andrew Blauvelt, Howard Sofen, C. Papavassilis, Thierry Passeron, David Rosmarin and Albert Wolkerstorfer and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

M. Ruer‐Mulard

12 papers receiving 512 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

2022 133 citations David Rosmarin, Thierry Passeron et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Ruer‐Mulard France	7	376	288	98	73	68	18	522
Alexandra Gruber‐Wackernagel Austria	15	403 1.1×	487 1.7×	81 0.8×	93 1.3×	42 0.6×	28	690
Keith H. Loven United States	10	261 0.7×	448 1.6×	62 0.6×	34 0.5×	54 0.8×	11	650
Eleonora Cinelli Italy	15	363 1.0×	328 1.1×	23 0.2×	60 0.8×	40 0.6×	36	540
Bruno de Oliveira Rocha Brazil	8	294 0.8×	144 0.5×	37 0.4×	66 0.9×	78 1.1×	16	428
R.E. Schopf Germany	9	332 0.9×	144 0.5×	139 1.4×	46 0.6×	107 1.6×	17	585
Caterina Schipani Italy	7	259 0.7×	181 0.6×	58 0.6×	54 0.7×	86 1.3×	11	395
Chanisada Wongpraparut Thailand	13	192 0.5×	195 0.7×	79 0.8×	36 0.5×	50 0.7×	49	369
Maria de Fátima Santos Paim de Oliveira Brazil	6	293 0.8×	135 0.5×	33 0.3×	58 0.8×	47 0.7×	9	383
Aida Pašić Croatia	11	163 0.4×	216 0.8×	58 0.6×	35 0.5×	30 0.4×	39	378
Fikret Kölemen Türkiye	12	188 0.5×	205 0.7×	106 1.1×	33 0.5×	69 1.0×	13	383

Countries citing papers authored by M. Ruer‐Mulard

Since Specialization

Citations

This map shows the geographic impact of M. Ruer‐Mulard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Ruer‐Mulard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Ruer‐Mulard more than expected).

Fields of papers citing papers by M. Ruer‐Mulard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Ruer‐Mulard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Ruer‐Mulard. The network helps show where M. Ruer‐Mulard may publish in the future.

Co-authorship network of co-authors of M. Ruer‐Mulard

This figure shows the co-authorship network connecting the top 25 collaborators of M. Ruer‐Mulard. A scholar is included among the top collaborators of M. Ruer‐Mulard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Ruer‐Mulard. M. Ruer‐Mulard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Rosmarin, David, Thierry Passeron, Amit G. Pandya, et al.. (2025). Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication. Therapeutic Advances in Chronic Disease. 16. 404426822–404426822.

Rosmarin, David, Thierry Passeron, Amit G. Pandya, et al.. (2022). Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine. 387(16). 1445–1455. 133 indexed citations breakdown →

Giordano‐Labadie, F., Pierre‐André Bécherel, P. Pralong, et al.. (2021). Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study. European Journal of Dermatology. 31(2). 217–224. 1 indexed citations

Mahé, E., et al.. (2020). Prescriptions hors AMM (autorisation de mise sur le marché) dans le psoriasis de l’enfant. Annales de Dermatologie et de Vénéréologie. 147(6-7). 429–438. 4 indexed citations

Richard, M.‐A., J.‐P. Lacour, Maria Polina Konstantinou, et al.. (2020). Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study. Journal of the European Academy of Dermatology and Venereology. 35(3). 677–684. 6 indexed citations

Mahé, E., F. Maccari, M. Ruer‐Mulard, et al.. (2019). Psoriasis de l’enfant vu en milieu libéral : les aspects cliniques et épidémiologiques diffèrent des données habituellement publiées. Annales de Dermatologie et de Vénéréologie. 146(5). 354–362. 9 indexed citations

Mahé, E., Alain Beauchet, Z. Reguiaï, et al.. (2017). Socioeconomic Inequalities and Severity of Plaque Psoriasis at a First Consultation in Dermatology Centers. Acta Dermato Venereologica. 97(5). 632–638. 20 indexed citations

Maccari, F., S. Hadj‐Rabia, M.‐L. Sigal, et al.. (2017). Rhumatisme psoriasique en France, du nourrisson à la personne âgée : données de deux études transversales multicentriques. Annales de Dermatologie et de Vénéréologie. 145(1). 13–20. 3 indexed citations

Richard, M.‐A., J.‐P. Lacour, M. Ruer‐Mulard, et al.. (2017). Évaluation de l’efficacité du secukinumab à l’aide de l’indice simplifié du Psoriasis : résultat d’une étude clinique prospective. Annales de Dermatologie et de Vénéréologie. 144(12). S260–S261.

10.

Paul, C., J.‐P. Lacour, A. Khemis, et al.. (2016). Évaluation de la tolérance du sécukinumab chez les patients atteints de psoriasis en plaques modéré à sévère : résultats à 2 ans. Annales de Dermatologie et de Vénéréologie. 143(12). S192–S192.

11.

Lacour, J.‐P., M. Ruer‐Mulard, A. Khemis, et al.. (2016). Supériorité du sécukinumab sur l’ustékinumab dans le psoriasis en plaques modéré à sévère de l’adulte : résultats de l’étude CLEAR à 1 an. Annales de Dermatologie et de Vénéréologie. 143(12). S191–S192.

12.

Lacour, J.‐P., A. Khemis, C. Paul, et al.. (2016). Infections à Candida et infections récidivantes : analyse de 10 études cliniques de phases 2 et 3 de sécukinumab dans le psoriasis modéré à sévère. Annales de Dermatologie et de Vénéréologie. 143(12). S257–S258.

13.

Descamps, V., E. Mahé, F. Maccari, et al.. (2014). Severe androgenetic alopecia as a proxy of metabolic syndrome in male psoriatic patients older than 59 years. European Journal of Dermatology. 24(3). 356–360. 4 indexed citations

14.

Blauvelt, Andrew, Jörg C. Prinz, Alice B. Gottlieb, et al.. (2014). Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). British Journal of Dermatology. 172(2). 484–493. 266 indexed citations

15.

Mahé, E., F. Maccari, Alain Beauchet, et al.. (2013). Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. British Journal of Dermatology. 169(4). 889–895. 40 indexed citations

16.

Mahé, E., F. Maccari, Z. Reguiaï, et al.. (2013). La sévérité du psoriasis lors d’une première consultation en dermatologie est-elle corrélée au statut socio-économique du patient ?. Annales de Dermatologie et de Vénéréologie. 140(12). S399–S400.

17.

Ruer‐Mulard, M., Werner Aberer, Anthony Gunstone, et al.. (2009). Twice‐daily versus Once‐daily Applications of Pimecrolimus Cream 1% for the Prevention of Disease Relapse in Pediatric Patients with Atopic Dermatitis. Pediatric Dermatology. 26(5). 551–558. 32 indexed citations

18.

Papp, Kim, et al.. (2004). Pimecrolimus cream 1% provides effective long-term control of atopic dermatitis in infants. Journal of the American Academy of Dermatology. 50(3). P65–P65. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact